Clinical trials for Lung cancer
323 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06265727
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Corbus Pharmaceuticals Inc.
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT05410145
#2023-508517-16-00
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
D3 Bio (Wuxi) Co., Ltd
Phase 1 / Phase 2
Lung cancer
#NCT06362252
#2023-509629-36-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
8 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2
Lung cancer
#NCT06669117
#2024-512760-64-00
Parties 2a et 2b
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06669117
#2024-512760-64-00
Partie 1 (Escalade de dose)
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2
Lung cancer
#NCT05118789
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ROS-1
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2
Lung cancer
#NCT05118789
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ROS-1
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2
Lung cancer
#NCT05937906
#2023-508477-87-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required PDL1 statuses
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
ROS-1
1 recruiting site
Centre Georges François Leclerc
Phase 1 / Phase 2
Lung cancer
#NCT06162221
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12D
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2
Lung cancer
#NCT06162221
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12D
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Revolution Medicines, Inc.